BBIO Stock Overview
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BridgeBio Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.03 |
| 52 Week High | US$44.32 |
| 52 Week Low | US$12.75 |
| Beta | 1.03 |
| 1 Month Change | -14.84% |
| 3 Month Change | -30.61% |
| 1 Year Change | 75.16% |
| 3 Year Change | -55.49% |
| 5 Year Change | n/a |
| Change since IPO | -9.15% |
Recent News & Updates
Recent updates
BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
Jan 11Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Nov 06
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jul 02New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
May 09Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook
Feb 28Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts
Jan 09BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status
Oct 11BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU
Sep 20BridgeBio Pharma: Down But Not Out
Aug 31BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders
Aug 18Industry Analysts Just Upgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts By 33%
Aug 10BridgeBio Pharma GAAP EPS of -$0.07 beats by $0.65, revenue of $73.75M beats by $48.75M
Aug 04BridgeBio, Sentynl's Nulibry get EMA panel nod for approval in EU
Jul 25BridgeBio Pharma: Yet To Be Proven Business Model
Jun 09News Flash: Analysts Just Made A Dazzling Upgrade To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Forecasts
May 22Analysts Have Just Cut Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Estimates By 54%
May 06Shareholder Returns
| BBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 1.0% | 1.2% |
| 1Y | 75.2% | 0.7% | 24.9% |
Return vs Industry: BBIO exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: BBIO exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| BBIO volatility | |
|---|---|
| BBIO Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BBIO's share price has been volatile over the past 3 months.
Volatility Over Time: BBIO's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 553 | Neil Kumar | bridgebio.com |
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
BridgeBio Pharma, Inc. Fundamentals Summary
| BBIO fundamental statistics | |
|---|---|
| Market cap | US$4.70b |
| Earnings (TTM) | -US$643.20m |
| Revenue (TTM) | US$9.30m |
496.3x
P/S Ratio-7.2x
P/E RatioIs BBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBIO income statement (TTM) | |
|---|---|
| Revenue | US$9.30m |
| Cost of Revenue | US$2.45m |
| Gross Profit | US$6.86m |
| Other Expenses | US$650.06m |
| Earnings | -US$643.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.49 |
| Gross Margin | 73.71% |
| Net Profit Margin | -6,913.92% |
| Debt/Equity Ratio | -128.6% |
How did BBIO perform over the long term?
See historical performance and comparison